Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open-label ...

For this understudied population, the findings may offer some reassurance as apixaban is already the most prescribed OAC in ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

A. Eliquis (apixaban) is a lifesaving anticoagulant that reduces the risk of blood clots that could cause a stroke. The price in the U.S. is more than $600 for a month’s supply. That’s with a coupon ...

Welcome to Medicare Part D, where your prescription drugs come with co-pays and co-insurance. If you thought co-pays and ...

The mean follow-up duration was 20 months. In the NOAC group, apixaban (Eliquis; Bristol Myers Squibb/Pfizer) was used in four trials, rivaroxaban (Xarelto; Janssen/Bayer) in two trials, dabigatran ...

The study confirmed that TAH3311 is bioequivalent to U.S. and European reference Apixaban tablets (Eliquis®) under fasting conditions, with Cmax and AUC values falling within the regulatory ...

aspirin.” The analysis included nine trials, all of which compared apixaban (Eliquis, Bristol Myers Squibb/Pfizer), dabigatran (Pradaxa, Boehringer Ingelheim) or rivaroxaban (Xarelto ...

Among those assigned to a DOAC, 53.8% used apixaban (Eliquis, Bristol Myers Squibb/Pfizer), 20.9% used dabigatran (Pradaxa, Boehringer Ingelheim), 18.4% used edoxaban (Savaysa, Daiichi Sankyo ...

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...